BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Pharma QC

Fresenius Kabi And TQ Therapeutics Sign Strategic Agreement To Scale T Cell Manufacturing For Cell And Gene Therapy

Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under...

January 16, 2026 | News

Novartis Secures Worldwide Licence To PepLib Peptide Asset To Expand Radioligand Therapy Pipeline

Zonsen PepLib Biotech Inc. announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in t...

January 15, 2026 | News

Oricell Raises 70M$ In Series C1 To Advance First In Class CAR T Therapy For Liver Cancer

Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced the closing of a $70M Ser...

January 14, 2026 | News

WuXi Biologics Secures UK MHRA GMP Clearance For Wuxi Ophthalmic Manufacturing Sites

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing ...

January 14, 2026 | News

Formosa Pharmaceuticals Secures Strategic Korea Commercial Partner For Its FDA Approved Ophthalmic Therapy

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Sam...

January 13, 2026 | News

FDA Signals A Faster Regulatory Path For Cell And Gene Therapies

The U.S. Food and Drug Administration announced it is sharing information about the agency’s flexible appro...

January 13, 2026 | News

Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal To Deepen Oral Inflammation Pipeline

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on ...

January 09, 2026 | News

Sidewinder Therapeutics Secures Multi Target ADC Licensing Agreement With Lonza

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline...

January 08, 2026 | News

Title21 Acquires MyCellHub To Strengthen Digital Manufacturing And Quality Leadership

Strategic acquisition accelerates Title21’s mission to deliver comprehensive, compliant, and integrated digital solutions for regulated healthcare an...

January 08, 2026 | News

ProBioGen Signs Master Service Agreement With Zag Bio To Advance Thymus Targeted Antibody Programme

ProBioGen announced the signing of a Master Service Agreement ("MSA") with Zag Bio, Inc., a biotechnology company developing thymus-targete...

January 07, 2026 | News

Nona Biosciences Expands Integrated Framework To Support Early Clinical Development And IITs

Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announced the expansion o...

January 02, 2026 | News

Enveda Advances Third Asset Into The Clinic As FDA Clears IND For ENV 6946 In Inflammatory Bowel Disease

Enveda achieves a significant milestone with three assets now in clinical development, further validating its platform’s ability to deliver differe...

December 25, 2025 | News

Jacobio Pharma Strikes Global Deal With AstraZeneca For Pan KRAS Inhibitor JAB 23E73

Jacobio Pharma announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive ...

December 23, 2025 | News

PeptiDream Advances Oral Dual IL17 Inhibitor Into Clinical Development Portfolio

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) a...

December 19, 2025 | News

Stay Connected